News
News




Taivex’s anti-cancer oral drug T-1201 received Phase I IND approval by the US FDA to enter clinical development.
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1201 on December 15, 2020, to initiate phase I clinical trial for the treatment of advanced solid tumors. T-1201 is a small molecular IV anti-cancer drug licensed from National Health Research Institutes in 2016. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug …

T-1101 capsule initiated Phase I clinical study
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate Phase I clinical study in Taiwan. Patients with advanced tumors have been enrolled into an ongoing open-label, Phase I dose escalation study in Taiwan. Enrollment for this study in Taiwan started in Jan, 2021. Trial …

T-1101 capsule approved by the TFDA to start Phase I clinical study
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is new capsule form. T-1101 capsule IND application has been approved by FDA in Nov, 2020 and further by TFDA in Dec, 2020. T-1101: T-1101 Phase I trial is the first-in-human study conducted to evaluate the safety and tolerability of T-1101 capsule in patients with solid …

T-1101 capsule approved by the FDA to start Phase I clinical study
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1101 capsule on Nov. 2021, to initiate phase I clinical trial. T-1101: T-1101 acts through disrupting the interaction between Hec1 and Nek2 to leads to tumor cells apoptosis. T-1101 demonstrated potent anti-cancer activity in different mouse xenograft models of human cancers, including liver and triple negative breast cancer. In …

Taivex’s anti-cancer oral drug T-1201 received Phase I IND approval by the US FDA to enter clinical development.
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1201 on December 15, 2020, to initiate phase I clinical trial for the treatment of advanced solid tumors. T-1201 is a small molecular IV anti-cancer drug licensed from National Health Research Institutes in 2016. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug …

T-1101 capsule initiated Phase I clinical study
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate Phase I clinical study in Taiwan. Patients with advanced tumors have been enrolled into an ongoing open-label, Phase I dose escalation study in Taiwan. Enrollment for this study in Taiwan started in Jan, 2021. Trial …

T-1101 capsule approved by the TFDA to start Phase I clinical study
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is new capsule form. T-1101 capsule IND application has been approved by FDA in Nov, 2020 and further by TFDA in Dec, 2020. T-1101: T-1101 Phase I trial is the first-in-human study conducted to evaluate the safety and tolerability of T-1101 capsule in patients with solid …

T-1101 capsule approved by the FDA to start Phase I clinical study
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1101 capsule on Nov. 2021, to initiate phase I clinical trial. T-1101: T-1101 acts through disrupting the interaction between Hec1 and Nek2 to leads to tumor cells apoptosis. T-1101 demonstrated potent anti-cancer activity in different mouse xenograft models of human cancers, including liver and triple negative breast cancer. In …
Sorry, we couldn't find any posts. Please try a different search.




